Enanta Pharmaceuticals (ENTA) Equity Average (2013 - 2026)

Enanta Pharmaceuticals has reported Equity Average for 14 years, with the latest figure at $121.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 18.42% year-over-year to $121.6 million; the trailing twelve-month figure through Mar 2026 stood at $121.6 million (up 18.42% YoY), and the FY2025 full-year result was $96.8 million, down 43.99% from the prior year.
• Equity Average for Q1 2026 stood at $121.6 million, up from $95.7 million in the prior quarter.
• The five-year high for Equity Average was $371.5 million in Q1 2022, with the low at $72.0 million in Q3 2025.
• Historically, Equity Average has averaged $200.3 million across 5 years, with a median of $179.0 million in 2024.
• Annual changes were most pronounced in 2025 — Equity Average tumbled 48.15% — and 2026, when it gained 18.42%.
• Enanta Pharmaceuticals' Equity Average stood at $311.1 million in 2022, then sank by 34.32% to $204.3 million in 2023, then plunged by 41.11% to $120.3 million in 2024, then fell by 20.5% to $95.7 million in 2025, then grew by 27.11% to $121.6 million in 2026.
• The last three Equity Average figures came in at $121.6 million (Q1 2026), $95.7 million (Q4 2025), and $72.0 million (Q3 2025), per Business Quant data.